News >

FDA Approves Carfilzomib for Relapsed Multiple Myeloma

Ben Leach
Published: Monday, Jul 23, 2012

Dr. Richard Pazdur

Richard Pazdur, MD

The FDA approved carfilzomib (Kyprolis, Onyx) for patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. While there was some concern over potentially lethal side effects during the time that the FDA reviewed the drug, the government agency decided that the benefits outweigh the risks.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication